We develop antibody-based therapies targeting IL1RAP

See our pipeline

Our goal is to treat cancer as well as inflammatory and autoimmune diseases

See our clinical program

Strong results provide support for our development programs

See our company presentation

2025-10-01Interview with Redeye

2025-10-01Interview with Redeye

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference

Watch the interview here

2025-07-15 Interview with Redeye

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical

Watch the interview here

2025-07-15 Interview with Redeye

2025-06-11 Redeye Investor Forum, Stockholm

2025-06-11 Redeye Investor Forum, Stockholm

Interim CEO Damian Marron presents at Redeye Investor Forum, Stockholm

Watch the presentation here

Press releases

2025-10-02 (R) Cantargia appoints Dr. Wolfram Dempke as Chief Medical Officer

2025-10-01 Cantargia presents data at an AACR Conference strengthening IL1RAP as a targetable hallmark in PDAC

2025-09-11 (R) Cantargia closes the acquisition of CAN10 by Otsuka

(R) = Regulatory press releases

Analysis

2025-07-18, Redeye analysis of Cantargia

2025-07-15, Redeye analysis of Cantargia

2025-06-11, Redeye analysis of Cantargia

2025-05-12, Redeye analysis of Cantargia

Current corporate presentation

Download the corporate presentation as PDF

Other presentations

2025-09-23, Presentation, BioStock – Investing in Life Science, Stockholm

2025-06-11, Video, Redeye Investor forum, Stockholm

2025-03-26, Video, H.C. Wainwright Annual Autoimmune & Inflammatory Virtual Conference 2025

2025-02-11, Video, Oppenheimer 35th Annual Healthcare Life Sciences Conference

2025-01-22, Video, Redeye Fight Cancer Event 2025